![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
SelfJect (repository corticotropin) is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants & children under 2 years of age and exacerbations of multiple sclerosis in adults.
Lead Product(s): Corticotropin
Therapeutic Area: Neurology Product Name: SelfJect
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2024
Details:
Cortrophin Gel (repository corticotropin injection) is an adrenocorticotropic hormone, which is indicated for acute gouty arthritis and rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; and ankylosing spondylitis.
Lead Product(s): Corticotropin
Therapeutic Area: Rheumatology Product Name: Cortrophin
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Retrospective medical chart review subgroup analysis showed Acthar Gel (corticotropin) was associated with overall symptom improvement and reduction in use of concomitant medications in African Americans.
Lead Product(s): Corticotropin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Acthar
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides. Acthar Gel is approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for short-term administration in RA.
Lead Product(s): Corticotropin
Therapeutic Area: Immunology Product Name: Acthar
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Purified Cortrophin™ Gel is purified corticotropin (ACTH) used for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (MS) and rheumatoid arthritis (RA).
Lead Product(s): Corticotropin
Therapeutic Area: Immunology Product Name: Cortrophin Gel
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
Purified Cortrophin Gel (Repository Corticotropin Injection USP) is a purified adrenocorticotropic hormone (ACTH) previously approved in the U.S. for multiple indications including multiple sclerosis (MS), rheumatoid arthritis (RA), and nephrotic syndrome (NS).
Lead Product(s): Corticotropin
Therapeutic Area: Immunology Product Name: Purified Cortrophin Gel
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
AmbioPharm will manufacture the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organization will exclusively supply Upsher-Smith with the finished product for sale in the United States.
Lead Product(s): Corticotropin
Therapeutic Area: Neurology Product Name: Acthar
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Upsher-Smith Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 07, 2020